Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifid-Triple-Viable
- Development stage
- Unknown
- Lead developer
- The Third Affiliated Hospital of Sun Yat-sen University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifid-Triple-Viable is a probiotic combination product manufactured by Neimengu Shuangqi Pharmaceutical, containing live strains of *Bifidobacterium longum*, *Lactobacillus delbrueckii subsp. bulgaricus*, and *Streptococcus thermophilus*. This formulation is designed to regulate intestinal flora and has been utilized in clinical research to evaluate its impact on the neonatal gut microbiota when administered to pregnant women. In a study led by the Third Affiliated Hospital of Sun Yat-Sen University, the blend was administered to women in their third trimester (from 32 weeks to delivery) to investigate the transmission and establishment of beneficial bacteria in infants. The product acts by colonizing the gastrointestinal tract, competing with pathogenic bacteria, and modulating the local immune environment to support a healthy microbiome and influence the early development of the neonatal gut microbiota.
- Brand names
- Bifid-Triple-ViablePeifeikangBifid Triple Viable
- Other names
- Probiotic Blend Oral TabletBifidobacterium longum + Lactobacillus delbrueckii bulgaricus + Streptococcus thermophiluslive combined Bifidobacterium and Lactobacillus tablets
Beyond the preview
Go deeper on Bifid-Triple-Viable.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifid-Triple-Viable.